Venture Capital

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

A $48M investment creates 67 homes for Montréal women, but its real impact is a new collaborative model that treats housing as essential healthcare.

An unsolicited bid from Paramount Skydance challenges Netflix's deal for WBD, sparking a high-stakes war for Hollywood's most iconic content library.

Prospect Enhanced Yield Fund's debut 9% distribution tempts income seekers, but a look into the structured credit market reveals a complex risk-reward.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

As the humanoid robotics market soars towards $7.7B, one firm is recruiting top talent to find the next big winner. What does this move signal to investors?

A new investment narrative targets 'essential' sectors. A deep dive reveals a complex mix of real strategy, verifiable progress, and pure promotion.

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

A junior miner's savvy strategy to re-examine old drill core could unlock new value, positioning its gold-lithium project at the nexus of today's markets.

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

A new clinical trial in Malaysia could democratize advanced cancer care, testing an affordable, donor-derived immunotherapy challenging costly personalized treatments.

Fate Therapeutics' latest data suggests its iPSC-derived CAR-T could revolutionize lupus care, moving cell therapy beyond cancer and into the mainstream.

A $1M deal between two junior miners isn't just about cash; it’s a strategic pivot that could offer a new blueprint for funding discovery.

A deepening corporate governance battle pits STAAR Surgical's board against its largest shareholder and all major proxy firms over a $1.5B Alcon deal.

Advanced aerial surveys reveal massive, untapped deposits of copper and nickel in Canada's far north, potentially rivaling the world's largest mineral reserves.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.